PERI-EDU University Education
Bone healing reflects both local surgical conditions and systemic regulation. Kidney, liver and intestinal disease can alter mineral balance, nutrition, immunity, medication handling or procedural safety. The diagnosis alone does not predict implant failure and should not replace individualized assessment.
Bone as a systemically regulated tissue
Bone continuously integrates endocrine, renal, hepatic, intestinal, vascular and immune signals. Osteoblasts, osteoclasts and osteocytes respond to calcium-phosphate balance, parathyroid hormone, vitamin D, inflammatory mediators and nutritional supply.
| System | Principal contribution | Potential relevance |
|---|---|---|
| Kidneys | Phosphate excretion, vitamin D activation, acid-base balance and endocrine signalling. | CKD may disturb turnover, mineralization and bone volume through CKD-MBD. |
| Liver | Protein synthesis, nutrient metabolism, inflammatory regulation and vitamin D 25-hydroxylation. | Advanced disease may affect nutrition, haemostasis, immunity and medicine handling. |
| Intestine | Absorption of minerals, vitamins, protein and medicines. | Inflammation, resection or malabsorption can create deficiencies and treatment complexity. |
| Local jaw environment | Blood supply, surgical trauma, implant stability, biofilm and loading. | Local factors remain necessary for interpreting every complication. |
CBCT provides information about bone dimensions and radiographic architecture. It cannot directly measure turnover, mineralization, collagen quality, marrow composition or cellular healing capacity.
Metabolic clustering
Diabetes, obesity, dyslipidaemia and metabolic dysfunction-associated steatotic liver disease often coexist. Chronic low-grade inflammation, oxidative stress and insulin resistance provide a plausible shared background, but they do not form one uniform implant-risk category.
Metabolic testing should answer a defined question. Ordering glucose, lipid, inflammatory, vitamin D, PTH and organ panels for every implant candidate risks incidental findings and false certainty.
Chronic kidney disease and CKD-MBD
Chronic kidney disease-mineral and bone disorder is a systemic disorder of mineral and skeletal metabolism caused by CKD. It can include biochemical abnormalities, altered bone turnover or mineralization, fractures and vascular or soft-tissue calcification.
| Component | Change in CKD | Clinical meaning |
|---|---|---|
| Phosphate and FGF-23 | Phosphate retention and increased FGF-23 may occur as kidney function declines. | They contribute to reduced calcitriol and altered mineral regulation. |
| Vitamin D metabolism | Renal activation becomes impaired. | This may reduce calcium absorption and contribute to secondary hyperparathyroidism. |
| Parathyroid hormone | PTH may rise in response to mineral imbalance. | One value requires trend and CKD-stage context. |
| Bone turnover | Turnover may be high, low or mixed. | Excessive resorption and suppressed remodelling can both affect healing. |
| Anaemia and uraemia | Advanced CKD can affect oxygen delivery, immunity, bleeding and drug clearance. | Procedural implications extend beyond bone metabolism. |
KDIGO recommends interpretation of calcium, phosphate and PTH together and as trends rather than isolated values. The nephrology team determines monitoring and treatment according to CKD stage and current therapy.
PTH, vitamin D and sclerostin
PTH responds to calcium-phosphate balance, vitamin D supports intestinal calcium absorption and bone physiology, and sclerostin limits Wnt/beta-catenin signalling in osteoblast-lineage cells.
- Interpret PTH with CKD stage, calcium, phosphate, vitamin D status and serial change.
- Do not use one universal dental vitamin D target or promise implant benefit from supplementation.
- Interpret calcium and phosphate within kidney function and treatment context.
- Remember that total alkaline phosphatase does not originate only from bone.
- Sclerostin has no routine role in implant qualification.
PTH, calcium, phosphate, magnesium, alkaline phosphatase and 25-hydroxyvitamin D should not form an automatic implant panel. Testing should follow CKD stage, malabsorption, fracture risk or another defined medical indication.
Liver disease and implant planning
The implications of liver disease depend on aetiology and severity. MASLD commonly reflects insulin resistance and cardiometabolic clustering. Advanced fibrosis, cirrhosis or decompensation can add nutritional, haemostatic, immune and medication-related concerns that simple steatosis does not imply.
| Liver context | Potential relevance | Assessment boundary |
|---|---|---|
| MASLD without advanced disease | Signals metabolic dysfunction and cardiovascular risk. | Does not by itself prove impaired coagulation or healing. |
| Advanced fibrosis or cirrhosis | May involve thrombocytopenia, altered drug handling, malnutrition and infection risk. | Routine coagulation tests incompletely represent haemostasis in cirrhosis. |
| Decompensated disease | Ascites, encephalopathy, variceal bleeding or jaundice indicate major instability. | Elective invasive care requires specialist coordination. |
| Transplantation | Immunosuppression and current organ function affect timing and care. | Do not independently alter immunosuppressive therapy. |
Liver disease should not be treated as synonymous with bleeding. Haemostatic testing and any correction plan require diagnosis-specific medical interpretation.
Inflammatory bowel disease and malabsorption
Active inflammation, intestinal resection, corticosteroid exposure, biologic therapy, anaemia and nutritional status may matter more than the inflammatory bowel disease label alone. Evidence concerning dental implant outcomes remains sparse and mainly involves Crohn disease.
- Clarify disease activity, recent flares and the treating clinical team.
- Consider targeted assessment of iron, vitamin B12, folate, vitamin D, calcium, magnesium or protein status when indicated.
- Record corticosteroid dose and duration.
- Do not independently interrupt biologic or other immunomodulatory therapy.
- Stabilize periodontal and peri-implant inflammation and provide a maintainable prosthetic design.
No gut or oral microbiome test currently determines implant eligibility. Probiotics or restrictive diets should not replace established medical and dental care.
Medication and comorbidity review
| Exposure | Possible relevance | Safe principle |
|---|---|---|
| Corticosteroids | Bone loss, hyperglycaemia, infection response and possible adrenal suppression. | Do not change treatment independently. |
| Immunosuppressants and biologics | Drug-specific infection and healing considerations. | Coordinate only when procedure and disease status justify it. |
| Antiresorptives | MRONJ risk depends on agent, indication, dose, route and duration. | Use a separate medication-specific assessment. |
| SSRIs | Observational studies report possible associations with bone and implant outcomes. | Confounding limits causal inference; use is not an automatic contraindication. |
| Renally or hepatically cleared medicines | Accumulation or toxicity may occur when organ function declines. | Check current prescribing guidance and coordinate dose decisions. |
A targeted pre-operative pathway
- Define the condition: record organ diagnosis, stage, activity and complications.
- Review treatment: document medicines, dialysis or transplant schedule and recent changes.
- Establish local readiness: assess periodontitis, plaque, infection, anatomy and prosthetic access.
- Use existing medical data: review recent results before ordering additional tests.
- Request targeted information: ask about stability, haemostasis, infection, drug dosing or mineral disorder.
- Adapt treatment: consider staging, procedural complexity, healing review and individualized maintenance.
CRP and CBC-derived inflammatory indices are nonspecific and should not function as universal implant screens. Acute organ decompensation, uncontrolled systemic infection or major unexplained abnormalities require medical assessment before elective surgery.
Clinical synthesis
- Kidney, liver and intestinal diseases affect bone through different pathways and at different levels of severity.
- CBCT appearance alone does not establish biological bone quality.
- Interpret CKD-MBD markers as patterns and trends within CKD-stage context.
- Distinguish MASLD from advanced fibrosis, cirrhosis and decompensated liver disease.
- Assess IBD through activity, malabsorption, medication and nutritional status.
- Avoid universal laboratory panels and unvalidated biomarker cutoffs.
- Do not independently interrupt immunosuppression, corticosteroids or other essential treatment.
Download the full educational material
The full PDF expands the kidney-bone, liver-bone and gut-bone pathways, CKD-MBD interpretation, medication review and targeted pre-operative decision process.
Download the full educational material (PDF)
Selected references
- KDIGO. 2017 Clinical Practice Guideline Update for CKD-MBD. Kidney International Supplements. 2017;7:1-59.
- Ketteler M, et al. Chronic kidney disease-mineral and bone disorder: conclusions from a KDIGO Controversies Conference. 2025.
- Kanjevac T, et al. Impact of CKD-MBD on jaw and alveolar bone metabolism. 2018. PMID: 29459907.
- Alla I, et al. Implant survival in patients with chronic kidney disease. 2023. PMID: 36767768.
- EASL-EASD-EASO. Clinical Practice Guidelines on the management of MASLD. Journal of Hepatology. 2024.
- Voina-Tonea A, et al. Dental implant failure in patients with inflammatory bowel disease. 2022. PMID: 35334519.
- Duttenhoefer F, et al. Dental implants in immunocompromised patients. 2019. PMID: 31776815.
Explore related PERI-EDU resources
#UniversityEducation #OnlineCourses #ClinicalCases #PERIEDU #CKDMBD #MASLD #InflammatoryBowelDisease #ImplantHealing
This educational material does not replace nephrology, hepatology, gastroenterology or individualized medical management.
This work was co-funded by the European Union under grant agreement No. 2024-1-PL01-KA220-HED-000251208. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the Foundation for the Development of the Education System (FRSE). Neither the European Union nor FRSE can be held responsible for them.